Marta Peñas-Prado - Concepedia

Author

Marta Peñas-Prado

The University of Texas MD Anderson Cancer Center

Also Known As

A. Melhem-Bertrandt, Anita Mahajan, Edward Pan, M Penas-Prado, M. Penas-Prado, Marta Penas-Prado, Marta Penas‐Prado, Marta Peñas-Prado, NCI-CONNECT Adult Medulloblastoma Workshop

190

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center National Cancer Institute National Institutes of Health Center for Cancer Research University of California, San Francisco

About

Marta Peñas-Prado is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and glioma.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	483
2	Health Sciences	7	7	233
3	Immunology	2	2	35
4	Biostatistics	1	1	35
5	Health Policy	1	1	29

Marta Peñas-Prado

Publications

Citations

H-Index

Page 1

	Year	Citations
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial Ingo K. Mellinghoff, Marta Peñas-Prado, Katherine B. Peters, Clinical Cancer Research	2021	234
An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825 Haley Gittleman, D. Lim, Michael W. Kattan, Neuro-Oncology	2016	170
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages John de Groot, Marta Peñas-Prado, Kristin Alfaro-Munoz, Neuro-Oncology	2019	158
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study Martin J. van den Bent, Hui Gan, Andrew B. Lassman, Cancer Chemotherapy and Pharmacology	2017	130
A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma Paul D. Brown, Caroline Chung, Diane D. Liu, Neuro-Oncology	2021	107
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with<i>EGFR</i>-amplified, recurrent glioblastoma: results from an international phase I multicenter trial Andrew B. Lassman, Martin J. van den Bent, Hui Gan, Neuro-Oncology	2018	94
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma Marta Peñas-Prado, Kenneth R. Hess, Michael Fisch, Neuro-Oncology	2014	76
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813 Susan M. Chang, J. Gregory Cairncross, Mark R. Gilbert, Neuro-Oncology	2016	75
NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma Mark R. Gilbert, Stephanie L. Pugh, Ken Aldape, Journal of Neuro-Oncology Neuro-oncologyHealth SciencesMedicineMetronomic TherapyHigh-grade Gliomas	2016	70
Phase 1 lead‐in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma Stefania Maraka, Morris D. Groves, Aaron Mammoser, Cancer	2018	68

Page 1